184 related articles for article (PubMed ID: 38162668)
21. Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
Zhang W; Luo C; Zhang ZY; Zhang BX; Chen XP
Front Immunol; 2022; 13():1079342. PubMed ID: 36700218
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
23. Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
Gbolahan O; Hashemi-Sadraei N; O'Neil B
J Natl Compr Canc Netw; 2019 Jun; 17(6):644-648. PubMed ID: 31200359
[TBL] [Abstract][Full Text] [Related]
24. Cholangiocarcinoma treatment.
Charbel H; Al-Kawas FH
Curr Gastroenterol Rep; 2012 Dec; 14(6):528-33. PubMed ID: 22968375
[TBL] [Abstract][Full Text] [Related]
25. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO).
Elias C; Zeidan YH; Bouferraa Y; Mukherji D; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
BMC Cancer; 2022 Dec; 22(1):1296. PubMed ID: 36503610
[TBL] [Abstract][Full Text] [Related]
26. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment.
Cholangiocarcinoma Working Group
Dig Liver Dis; 2020 Dec; 52(12):1430-1442. PubMed ID: 32952071
[TBL] [Abstract][Full Text] [Related]
27. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of Advanced Cholangiocarcinoma in the Palliative Care Setting: A Series of 201 Cases.
Zeng T; Tao C; Yang G; Chen X; Yuan Z
Altern Ther Health Med; 2022 Feb; 28(2):24-31. PubMed ID: 34653023
[TBL] [Abstract][Full Text] [Related]
29. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma.
Harewood GC; Baron TH; Rumalla A; Wang KK; Gores GJ; Stadheim LM; de Groen PC
J Gastroenterol Hepatol; 2005 Mar; 20(3):415-20. PubMed ID: 15740486
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma.
Zhang N; Yu BR; Wang YX; Zhao YM; Zhou JM; Wang M; Wang LR; Lin ZH; Zhang T; Wang L
J Dig Dis; 2022 Aug; 23(8-9):535-545. PubMed ID: 36148493
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival after multimodal therapy in a patient demonstrating intrahepatic cholangiocarcinoma with hilar invasion and intrahepatic metastases.
Morinaga S; Yamamoto Y; Sugano N; Wada H; Shiozawa M; Akaike M; Sugimasa Y
Int J Clin Oncol; 2008 Aug; 13(4):361-4. PubMed ID: 18704639
[TBL] [Abstract][Full Text] [Related]
32. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma.
Hong K; Geschwind JF
Semin Oncol; 2010 Apr; 37(2):110-7. PubMed ID: 20494703
[TBL] [Abstract][Full Text] [Related]
33. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma.
Isayama H; Tsujino T; Nakai Y; Sasaki T; Nakagawa K; Yamashita H; Aoki T; Koike K
World J Gastroenterol; 2012 May; 18(19):2364-70. PubMed ID: 22654427
[TBL] [Abstract][Full Text] [Related]
34. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies.
Yu X; Zhu L; Wang T; Chen J
Front Immunol; 2023; 14():1037945. PubMed ID: 37138880
[TBL] [Abstract][Full Text] [Related]
35. Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases.
Jiang W; Zeng ZC; Tang ZY; Fan J; Zhou J; Zeng MS; Zhang JY; Chen YX; Tan YS
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1323-31. PubMed ID: 20130909
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
Liu J; Shu J
Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
[TBL] [Abstract][Full Text] [Related]
37. Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis.
Garajová I; Gelsomino F; Salati M; Leonardi F; De Lorenzo S; Granito A; Tovoli F
Curr Oncol; 2023 Feb; 30(3):2613-2624. PubMed ID: 36975412
[TBL] [Abstract][Full Text] [Related]
38. [A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Hayashi H; Beppu T; Ishiko T; Mizumoto T; Masuda T; Okabe K; Baba Y; Okabe H; Takamori H; Kanemitsu K; Hiroto M; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1941-3. PubMed ID: 17212153
[TBL] [Abstract][Full Text] [Related]
39. First Reported Case of Primary Intrahepatic Cholangiocarcinoma with Pure Squamous Cell Histology: A Case Report.
Lubana SS; Singh N; Seligman B; Tuli SS; Heimann DM
Am J Case Rep; 2015 Jul; 16():438-44. PubMed ID: 26158884
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors in cholangiocarcinoma.
Beri N
Immunotherapy; 2023 May; 15(7):541-551. PubMed ID: 37096964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
